Xtl Biopharmaceuticals XTLB
NASDAQ XTLB
$2.16 +0.03 (+1.41%)
As of: Oct 2, 2026 · 1:58 PM EDT

Xtl Biopharmaceuticals (XTLB) Liabilities from Discontinued Operations (2014 - 2015)

Updated

Xtl Biopharmaceuticals (XTLB) reported Liabilities from Discontinued Operations of -$449,000 for the quarter ended Dec 31, 2015, compared with $450,000 a year earlier.

Analysis

Xtl Biopharmaceuticals (XTLB) Liabilities from Discontinued Operations (2014 - 2015) Analysis & Trends

  • By year, Liabilities from Discontinued Operations came in at $450,000 in the year ended Dec 31, 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Xtl Biopharmaceuticals 2.27 Bn 2.27 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 -449,000.00
Jun 30, 2015 -449,000.00
Dec 31, 2014 450,000.00
API Access

Xtl Biopharmaceuticals Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=XTLB&period=max&api_key=YOUR_API_KEY